|

Program

Join ASM and IDSA for the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), a one-of-a-kind forum uniting scientist, clinicians, industry leaders, and policymakers to advance the global response to antimicrobial resistance. This groundbreaking event will showcase the latest in antimicrobial drug discovery, development, and implementation through a dynamic and collaborative program. 

Program highlights include: 

  •  Plenary sessions featuring world-renowned thought leaders 
  •  Scientific symposia exploring advanced topics in antimicrobial resistance 
  •  Industry programs highlighting innovative and emerging technologies
  •  Poster sessions presenting high-impact research from across disciplines 

Note: The following schedule is a long-form comprehensive look at the meeting, including session times, speakers and topics.

Wednesday, January 27 Thursday, January 28 Friday, January 29


Wednesday, January 27

8–9 a.m. Sponsored Breakfast
8–9:15 a.m.

Sponsored Pipeline Session

  • 8–9:15 a.m. | Industry Presentations
9–9:30 a.m. Break

Concurrent Sessions
9:30–10:30 a.m.

Concurrent Session 1: A Case of Recalcitrant Mycobacterium Abscessus in the Lung (Sponsored by AAC/JID)

  • 9:30–9:50 a.m. | Case Presentation
    Speaker: Charles Daley, M.D., National Jewish Health

  • 9:50–10:10 a.m. | ID/PK/PD Expert
    Speaker: Elisa Ignatius, M.D., Ph.D., Johns Hopkins University

  • 10:10–10:30 a.m. | Microbiologist
    Speaker: Monika Kumaraswamy, M.D., D(ABMM), University of Texas at Tyler

Concurrent Session 2: Structural Basis of β-lactamase Inhibition

  • 9:30–10 a.m. | Identifying Inhibitors of Antibiotic Resistance Enzymes using DNA-Encoded Chemical Libraries
    Speaker: Timothy Palzkill, Ph.D., Baylor College of Medicine

  • 10–10:30 a.m. | Inhibition of Metallo-β-lactamases, including S. maltophilia L1
    Speaker: Maria Fernanda Mojica, MSC, Ph.D., Case Western Reserve University

Concurrent Session 3: Combination Therapy Against Fungal Pathogens: PK/PD Considerations

  • 9:30–10 a.m. | Mechanism and Clinical Approaches
    Speaker: Dimitrios Kontoyiannis, M.D., MS, ScD, Ph.D., FACP, FIDSA, FECMM, FAAM, FAAAS, University of Texas MD Anderson Cancer Center

  • 10–10:30 a.m. | Pharmacologic Considerations
    Speaker: Melissa Johnson, Duke University School of Medicine
10:30–11 a.m. Break
11 a.m.–12:15 p.m.
 Plenary: New Antimicrobial Agents in The Pipeline
Moderator(s): Patricia Bradford, Ph.D., Antimicrobial Development Specialists LLC; Karen Bush, Ph.D., Indiana University
12:15–2:15 p.m. Lunch and Poster Session
2:15–3:30 p.m.

Plenary: Are Phages Ready for Prime Time?

  • 2:15–2:35 p.m. | Phage as Vaccines
    Speaker: Anthony Maresso, Ph.D., Baylor College of Medicine

  • 2:40–3 p.m. | PK/PD Considerations for Phage Therapy
    Speaker: Nicholas Smith, PharmD, Ph.D., SUNY Buffalo State University

  • 3:05–3:25 p.m. | Clinical Conundrums in Phage Therapy: New Data from Clinical Trials
    Speaker: Saima Aslam, M.D., University of California San Diego
3:30–4 p.m. Break
4–5:45 p.m.

Opening Plenary: AMR Solutions and Their Global Impact

  • 4–4:15 p.m. | Opening Words from IDSA and ASM Senior Leadership
    Speaker(s): TBD

  • 4:15–4:35 p.m. | Innovation to Address AMR: A Pharmaceutical Journey
    Speaker: Michael Dudley, PharmD, Qpex Biopharma

  • 4:35–4:55 p.m. | Non-Traditional Approaches for AMR
    Speaker: Scott Hultgren, Ph.D., Washington University

  • 4:55–5:15 p.m. | Tackling AMR in the Developing World, a Latin-American Experience
    Speaker: Maria V. Villegas, M.D., MSc, Universidad El Bosque

  • 5:15–5:35 p.m. | Fleming Initiative Grand Challenges
    Speaker: Lord Ara Darzi, PC, KBE, FRS, FMedSci, HonFREng, Imperial College London
5:45–7 p.m. Opening Reception

to top ^



Thursday, January 28

to top ^


7–8:15 a.m.

Beyond Resistance: Host, Microbiome, and Pathogen Drivers of Therapeutic Non-Responsiveness
Moderator: Michael Craig, MPP, Centers for Disease Control and Prevention (CDC)

  • 7–7:05 a.m. | Welcome and Introduction of Panelists
    Speaker: Michael Craig, MPP, Centers for Disease Control and Prevention (CDC)

  • 7:05–7:20 a.m. | What is Therapeutic Non-Responsiveness?
    Speaker: Alison Laufer Halpin, Ph.D., Centers for Disease Control and Prevention (CDC)

  • 7:20–7:35 a.m. | How Does Microbiome Dysbiosis Contribute to Therapeutic Non-Responsiveness in the Context of Recurrent and Chronic Infectious Disease?
    Speaker: Ryan Ranallo, Ph.D., National Institute of Allergy and Infectious Diseases (NIAID)

  • 7:35–8:10 a.m. | Panel Discussion: Innovative Solutions to Address TNR
    Speaker(s): Alison Laufer Halpin, Ph.D., Centers for Disease Control and Prevention (CDC); Ryan Ranallo, Ph.D., National Institute of Allergy and Infectious Diseases (NIAID); Sujan Reddy, M.D., MSc, Centers for Disease Control and Prevention (CDC)

  • 8:10–8:15 a.m. | Wrap-Up
    Speaker: Michael Craig, MPP, Centers for Disease Control and Prevention (CDC)

8–9 a.m. Industry & Science Breakfast Symposium
8–9:15 a.m. Sponsored Pipeline Session
  • 8–9:15 a.m. | Industry Presentations
8:30–9 a.m. Break
Concurrent Sessions
9–10 a.m.

Concurrent Session 1: A Case of Difficult to Treat Pseudomonas aeruginosa Infection (Sponsored by AAC/JID)

  • 9–9:20 a.m. | Case Presentation
    Speaker: Michael Satlin, M.D., Cornell University

  • 9:20–9:40 a.m. | Microbiologist
    Speaker: Rafael Cantón, Ph.D., Hospital Universitario Ramón y Cajal

  • 9:40–10 a.m. | PK/PD Expert
    Speaker: Jason Pogue, PharmD, BCPS, BCIDP, University of Michigan

Concurrent Session 2: Breakpoints for BLIs: A Tough Nut to Crack
Moderator: Amy Mathers, M.D., D(ABMM), University of Virginia

  • 9–10 a.m. | Panel Discussion Leader
    Speaker: William Miller, M.D., Houston Methodist

  • 9–10 a.m. | Panel Participants

Concurrent Session 3: ARLG Session – Transformational Findings and a Look to the Future

  • 9–9:20 a.m. | Clinical Studies Influencing Changes in Practice
    Speaker: Sarah Doernberg, M.D., MAS, University of California San Francisco

  • 9:20–9:40 a.m. | Diagnostic Studies
    Speaker: Ritu Banerjee, M.D., Ph.D., Vanderbilt University

  • 9:40–10 a.m. | Mentoring Early Clinical Investigators in AMR
    Speaker: Anthony Harris, M.D., MPH, University of Maryland
10–10:30 a.m. Break
10:30 a.m.–12 p.m.

Plenary: Outer Membrane as an Antimicrobial Target

  • 10:30–11 a.m. | OM Biogenesis
    Speaker: Anna Konovalova, Ph.D., University of Texas Health Science Center at Houston

  • 11–11:30 a.m. | Inhibition of Lipoprotein Trafficking and LPS Landscaping
    Speaker: Marcin Grabowicz, Ph.D., Emory University

  • 11:30 a.m.–12 p.m. | Inhibitors: Past, Present, and Future – Pipeline of LPS Transport/Biosynthesis Inhibitors
    Speaker: Man-Wah Tan, Ph.D., Genentech
12–2 p.m. Lunch and Poster Session
Concurrent Sessions
2–3:30 p.m.

Concurrent Session 1: Artificial Intelligence and Antibiotic Discovery

  • 2–2:30 p.m. | Accelerating Antibiotic Discovery with Generative AI
    Speaker: Akhila Kosaraju, M.D., Phare Bio

  • 2:30–3 p.m. | AI-Driven High Content Phenotypic Screening to Predict Antibiotic Mode of Action
    Speaker: Ivo Boneca, Ph.D., Institut Pasteur

  • 3–3:30 p.m. | Why Don’t We Have Any AI-Derived Antibiotics in the Clinic Yet?
    Speaker: Jonathan Stokes, Ph.D., McMaster University

Concurrent Session 2: Alternative Targets in Antibiotic Discovery

  • 2–2:30 p.m. | LolCDE Inhibitors and Efflux Evasion
    Speaker: Paul Hergenrother, Ph.D., University of Illinois Urbana-Champaign

  • 2:30–3 p.m. | FtsZ Inhibitors
    Speaker: Ajit Parhi, Ph.D., TAXIS Pharmaceuticals

  • 3–3:30 p.m. | DNA Synthesis Inhibitors
    Speaker: Thale Jarvis, Ph.D., Crestone Pharma

Concurrent Session 3: Non-Traditional and Emerging Approaches for AMR

  • 2–2:30 p.m. | Ecosystem of Vaccines for AMR: Unmet Needs and Competitive Landscape
    Speaker: Vega Masignani, Ph.D., CARB-X

  • 2:30–3 p.m. | Immuno-Prevention Against Staphylococcal Infections
    Speaker: Victor Torres, Ph.D., St. Jude Children’s Research Hospital

  • 3–3:30 p.m. | Microbiome Manipulation
    Speaker: Kevin Garey, PharmD, MS, FASHP, University of Houston
3:30–4 p.m. Break

4–5:15 p.m.

Plenary: Dissecting End Points for New Antibiotics
Moderator: Michael Craig, MPP, Centers for Disease Control and Prevention (CDC)

  • 4–4:45 p.m. | Outstanding Oral Abstract Presentations

  • 4:45–5:15 p.m. | Dissecting End Points for New Antibiotics
    Speaker: Scott Evans, M.S., Ph.D., George Washington University

6–7:30 p.m. Industry Symposia



Friday, January 29

to top ^

Concurrent Sessions
7:30–8:30 a.m.

Concurrent Session 1: T32 Trainee Session

Concurrent Session 2: Scientific Leadership is Needed for the Independent Panel on Evidence for Action Against AMR
Moderator: Kevin Outterson, J.D., LL.M., CARB-X

Concurrent Session 3: Novel Mechanistic Insights into Resistance in Non-Tuberculous Mycobacteria

  • 7:30–8 a.m. | Mechanisms of β-Lactam Resistance in Mycobacterium abscessus Speaker
    Speaker: Adrian Zelazny, Ph.D., D(ABMM), Department of Laboratory Medicine, NIH Clinical Center

  • 8–8:30 a.m. | TBD
    Speaker: Jakko van Ingen, M.D., Ph.D., Radboud University Medical Center
8:30–9 a.m. Break

Concurrent Sessions
9–10:30 a.m.

Concurrent Session 1: Emerging Resistance Mechanisms in Gram-Negative Bacteria

  • 9–9:30 a.m. | The Rise of PBP Mutations: Mechanisms, Clinical Implications, and Occupancy Strategies
    Speaker: Yohei Doi, M.D., Ph.D., University of Pittsburgh
  • 9:30–10 a.m. | New β-lactamase Inhibitor Escape Variants
    Speaker: Christophe Le Terrier, M.D., Ph.D., Université de Fribourg
  • 10–10:30 a.m. | Same Pumps, New Substrates: The Expanding Role of Cross-Class Antibiotic Efflux Pumps
    Speaker: Helen Zgurskaya, Ph.D., University of Oklahoma

Concurrent Session 2: Emerging Resistance Mechanisms in Gram-Positive Bacteria

  • 9–9:30 a.m. | Update in Cell Envelope Biology
    Speaker: Mariana Gomes de Pinho, Ph.D., ITQB Universidade NOVA de Lisboa
  • 9:30–10 a.m. | PBPs as β-lactamases
    Speaker: Rebecca Page, Ph.D., UCONN Health
  • 10–10:30 a.m. | Agr Deficiency and Tolerance in Biofilm Infection
    Speaker: Michael Otto, Ph.D., National Institutes of Health

Concurrent Session 3: Emergent Resistance Mechanisms in Fungi

  • 9–9:30 a.m. | Antifungal Resistance Epidemiology and Impact
    Speaker(s): Dallas Smith, PharmD, Centers for Disease Control and Prevention (CDC); Meghan Lyman, M.D., Centers for Disease Control and Prevention (CDC)

  • 9:30–10 a.m. | C. auris Emergence and Mechanisms
    Speaker: Jeff Rybak, PharmD, Ph.D., St. Jude Children’s Research Hospital

  • 10–10:30 a.m. | A. fumigatus Emergence and Mechanisms
    Speaker: Paul Verweij, M.D., F.E.C.M.M., Radboud University Nijmegen
10:30–11 a.m. Break
11 a.m.–12:15 p.m.

Closing Plenary: Discovering Antibiotics in the 21st Century
Moderator(s): Cesar A. Arias, M.D., MSc, Ph.D., Houston Methodist and Weill Cornell Medical College, IMARI 2027 Co-Chair; Greg Moeck, Ph.D., IMARI 2027 Co-Chair

  • 11–11:45 a.m. | Outstanding Oral Abstract Presentations

  • 11:45 a.m.–12:15 p.m. | Discovering Antibiotics in the 21st Century
    Speaker: Gerry Wright, Ph.D., FRSC, McMaster University